Literature DB >> 27673496

Design, synthesis and DNA-binding study of some novel morpholine linked thiazolidinone derivatives.

Javeed Ahmad War1, Santosh Kumar Srivastava2, Savitri Devi Srivastava1.   

Abstract

The emergence of multiple drug resistance amongst bacterial strains resulted in many clinical drugs to be ineffective. Being vulnerable to bacterial infections any lack in the development of new antimicrobial drugs could pose a serious threat to public health. Here we report design and synthesis of a novel class of morpholine linked thiazolidinone hybrid molecules. The compounds were characterized by FT-IR, NMR and HRMS techniques. Susceptibility tests showed that most of the synthesized molecules were highly active against multiple bacterial strains. Compound 3f displayed MIC values which were better than the standard drug for most of the tested strains. DNA being a well defined target for many antimicrobial drugs was probed as possible target for these synthetic molecules. DNA-binding study of 3f with sm-DNA was probed through UV-vis absorption, fluorescence quenching, gel electrophoresis and molecular docking techniques. The studies revealed that compound 3f has strong affinity towards DNA and binds at the minor groove. The docking studies revealed that the compound 3f shows preferential binding towards A/T residues.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  4-(2-Aminoethyl)morpholine; Broad spectrum antimicrobials; DNA-binding; Molecular docking

Mesh:

Substances:

Year:  2016        PMID: 27673496     DOI: 10.1016/j.saa.2016.07.054

Source DB:  PubMed          Journal:  Spectrochim Acta A Mol Biomol Spectrosc        ISSN: 1386-1425            Impact factor:   4.098


  1 in total

1.  Synthesis, Crystal Structures and Anticancer Studies of Morpholinyldithiocarbamato Cu(II) and Zn(II) Complexes.

Authors:  Peter A Ajibade; Fartisincha P Andrew; Nandipha L Botha; Nolwazi Solomane
Journal:  Molecules       Date:  2020-08-06       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.